

# The use of Helium in acute myocardial infarction trial (HAMI-trial).

Gepubliceerd: 14-01-2011 Laatste bijgewerkt: 18-08-2022

We hypothesize that helium postconditioning reduces ischemia reperfusion injury following an acute myocardial infarction and thereby reduces the size of infarction. Secondly, we hypothesize that this reduction leads to improved myocardial function,...

|                             |                          |
|-----------------------------|--------------------------|
| <b>Ethische beoordeling</b> | Positief advies          |
| <b>Status</b>               | Werving nog niet gestart |
| <b>Type aandoening</b>      | -                        |
| <b>Onderzoekstype</b>       | Interventie onderzoek    |

## Samenvatting

### ID

NL-OMON23814

### Bron

NTR

### Verkorte titel

HAMI-trial

### Aandoening

Acute myocardial infarction  
acute coronary syndrome  
ischemia reperfusion injury  
acuut hartinfarct  
acuut coronair syndroom  
ischemie reperfusie schade

## Ondersteuning

**Primaire sponsor:** Academical Medical Center, University of Amsterdam

**Overige ondersteuning:** ZonMw

## Onderzoeksproduct en/of interventie

## **Uitkomstmaten**

### **Primaire uitkomstmaten**

On day 4 after the PCI a CMR will be obtained. T-2 weighed imaging shows edema in the tissue which has been ischemic before and is therefore at risk for developing infarction. T-1 weighed imaging after the injection of gadolinium contrast marks the infarcted tissue. Primary endpoint is the total volume of infarction as proportion of the total volume of myocardium at risk.

## **Toelichting onderzoek**

### **Achtergrond van het onderzoek**

In patients with acute myocardial infarction swift revascularisation is the treatment of choice. However, even after PCI tissue damage continues: ischemia reperfusion injury. In animal models, helium inhalation has been shown to reduce this kind of damage. In this study we investigate whether cotreatment with helium during primary PCI reduces the size of myocardial infarction in patients.

### **Doel van het onderzoek**

We hypothesize that helium postconditioning reduces ischemia reperfusion injury following an acute myocardial infarction and thereby reduces the size of infarction. Secondly, we hypothesize that this reduction leads to improved myocardial function, less adverse events and less limitations during daily life of the respective patients.

### **Onderzoeksopzet**

Blood samples will be obtained for analysis of troponin T levels at baseline and at 6 hour intervals during the first two days. NT-proBNP levels will be determined at baseline, 6 hours, 12 hours, 24 hours, 48 hours and at 4 days and 4 months after the procedure. Analysis of all the samples will be done in the central laboratory for clinical chemistry at the AMC.

### **Onderzoeksproduct en/of interventie**

Helium inhalation (79%) starting directly after inclusion, until 10 minutes after opening of the target vessel.

## **Contactpersonen**

## **Publiek**

Postbus 22660, M0-126  
Daniel Brevoord  
Amsterdam 1100 DD  
The Netherlands  
+31 (0)20 5669111

## **Wetenschappelijk**

Postbus 22660, M0-126  
Daniel Brevoord  
Amsterdam 1100 DD  
The Netherlands  
+31 (0)20 5669111

## **Deelname eisen**

### **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

1. Age 18-75 years;
2. ST-elevation myocardial infarction;
3. Treatment with primary PCI;
4. Chest pain of <12 hours duration.

### **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

1. Left bundle branch block;
2. Previous myocardial infarction;
3. Fibrinolytic treatment in the previous 30 days;
4. Previous coronary artery bypass surgery;
5. Left main stenosis requiring coronary bypass surgery;

6. Severe heart failure as witnessed by any of the following:
- A. The need for mechanical ventilation;
  - B. The use of an intra-aortic balloon pump or Impella;
  - C. High catecholamine usage.
7. Usage of the anti-diabetic drug glibenclamide (this drug is known to block any conditioning effect);
8. Renal failure;
9. Inability to undergo MRI (e.g. due to the presence of pacemaker or ICD).

## Onderzoeksopzet

### Opzet

|                  |                       |
|------------------|-----------------------|
| Type:            | Interventie onderzoek |
| Onderzoeksmodel: | Parallel              |
| Toewijzing:      | Gerandomiseerd        |
| Blinding:        | Enkelblind            |
| Controle:        | Placebo               |

### Deelname

|                         |                          |
|-------------------------|--------------------------|
| Nederland               |                          |
| Status:                 | Werving nog niet gestart |
| (Verwachte) startdatum: | 01-02-2011               |
| Aantal proefpersonen:   | 70                       |
| Type:                   | Verwachte startdatum     |

## Ethische beoordeling

|                 |                  |
|-----------------|------------------|
| Positief advies |                  |
| Datum:          | 14-01-2011       |
| Soort:          | Eerste indiening |

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

| Register | ID |
|----------|----|
|----------|----|

|         |        |
|---------|--------|
| NTR-new | NL2566 |
|---------|--------|

|         |         |
|---------|---------|
| NTR-old | NTR2691 |
|---------|---------|

Ander register METC AMC Amsterdam / CCMO : 10/210 / NL 33604.018.10 ;

## Resultaten

### Samenvatting resultaten

N/A